Small cell lung cancer (SCLC) accounts for about 15% of lung cancer cases and is categorized into limited and extensive stages. Treatment options include radiation, chemotherapy, and immunotherapy ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed.

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Blood clots form in response to signals from the lungs of cancer patients -- not from other organ sites, as previously thought -- according to a preclinical study. Clots are the second-leading cause ...

Serplulimab is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC; Serplulimab is the first and only anti-PD-1 mAb approved in th ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

It specifically targets epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), according to the National Institute for Health and Care Excellence (Nice).

A new study shows that artificial intelligence (AI) can help doctors make better decisions when treating cancer. However, it also highlights challenges in how doctors and AI work together. The study ...

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.

As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.